INS and Obesity: In preclinical disease models, inhibition of Drp-1 demonstrated protective effects against cardiovascular diseases, including ischemia–reperfusion (I/R) injury to the brain [122,124] and heart [125], as well as metabolic diseases [126], improving insulin sensitivity, decreasing inflammation, and reducing body weight in diet-induced obesity models.